TITLE:
Efficacy and Safety of Basal-Supported Prandial GLP-1 Receptor Agonist Therapy
AUTHORS:
Taichi Nagahisa, Mitsuhisa Tabata, Satoru Yamada
KEYWORDS:
Basal Insulin, Combination Therapy, GLP-1 Receptor agonists, HbA1c, Type 2 Diabetes Mellitus
JOURNAL NAME:
Journal of Diabetes Mellitus,
Vol.7 No.3,
July
28,
2017
ABSTRACT: Aim: To assess the safety and efficacy of basal-supported prandial GLP-1 receptor
agonist therapy (BPT)* in type 2 diabetes mellitus (T2DM). Methods:
Patients with T2DM, who had previously received insulin injection therapy
and who had had their treatment switched to BPT (liraglutide), were retrospectively
recruited. The efficacy of BPT was assessed by determining changes
in HbA1c, body weight and total daily insulin dose from baseline to 4 months
after BPT initiation. Safety was assessed by comparing the frequency of hypoglycemic
episodes at baseline and after 4 months. The Wilcoxon test was
used to analyze changes in parameters throughout the study period. Results:
Twenty-nine patients, previously treated with basal-supported oral therapy
(BOT), basal-bolus insulin, or pre-mixed insulin, were recruited. When analyzed
together, there was no change in HbA1c throughout the study period,
but body weight decreased (baseline 68.8 ± 13.2 kg vs. month 4 67.3 ± 13.1 kg;
p Conclusion: BPT in T2DM was associated
with weight loss without changes in glycemic control over 4 months, suggesting
that it may be an effective and safe therapy.